Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for Nicotine Dependence in Overweight/Obese Smokers
NCT03712098Phase 2Completed
- Start
- Nov 2018
- Primary completion
- May 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in nicotine dependence comparing Liraglutide + Counseling with Placebo + Counseling (2 arms). Primary endpoint: 7-day Point Prevalence Smoking Abstinence at 32 weeks. Started Nov 2018; status: completed.
02
Drugs
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT03712098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03712098.